FY2024 Earnings Forecast for ALNY Issued By Leerink Partnrs

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) – Equities researchers at Leerink Partnrs lowered their FY2024 earnings per share estimates for Alnylam Pharmaceuticals in a research report issued on Tuesday, January 21st. Leerink Partnrs analyst M. Foroohar now anticipates that the biopharmaceutical company will post earnings of ($2.48) per share for the year, down from their prior estimate of ($1.74). The consensus estimate for Alnylam Pharmaceuticals’ current full-year earnings is ($2.18) per share. Leerink Partnrs also issued estimates for Alnylam Pharmaceuticals’ Q4 2024 earnings at ($0.94) EPS, FY2025 earnings at ($2.00) EPS and FY2026 earnings at $0.49 EPS.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last posted its quarterly earnings data on Thursday, October 31st. The biopharmaceutical company reported ($0.87) earnings per share for the quarter, missing the consensus estimate of ($0.51) by ($0.36). The business had revenue of $500.90 million during the quarter, compared to analyst estimates of $532.91 million. During the same quarter in the prior year, the company posted $1.15 earnings per share. The company’s revenue was down 33.3% on a year-over-year basis.

Several other brokerages have also recently weighed in on ALNY. Bank of America increased their target price on Alnylam Pharmaceuticals from $307.00 to $314.00 and gave the company a “buy” rating in a report on Monday, October 14th. Cantor Fitzgerald reiterated a “neutral” rating and issued a $220.00 price objective on shares of Alnylam Pharmaceuticals in a report on Friday, October 11th. William Blair reissued an “outperform” rating on shares of Alnylam Pharmaceuticals in a research report on Tuesday, November 19th. Barclays raised their price objective on Alnylam Pharmaceuticals from $295.00 to $329.00 and gave the company an “overweight” rating in a research report on Friday, November 1st. Finally, Sanford C. Bernstein reduced their price objective on Alnylam Pharmaceuticals from $314.00 to $310.00 and set an “outperform” rating for the company in a research report on Tuesday, January 7th. One equities research analyst has rated the stock with a sell rating, six have given a hold rating and nineteen have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $298.61.

Alnylam Pharmaceuticals Stock Up 0.6 %

Shares of NASDAQ ALNY opened at $266.54 on Thursday. The company has a debt-to-equity ratio of 31.64, a quick ratio of 2.69 and a current ratio of 2.75. The stock’s 50-day simple moving average is $245.91 and its two-hundred day simple moving average is $259.99. Alnylam Pharmaceuticals has a twelve month low of $141.98 and a twelve month high of $304.39.

Institutional Investors Weigh In On Alnylam Pharmaceuticals

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Dimensional Fund Advisors LP boosted its holdings in shares of Alnylam Pharmaceuticals by 4.3% in the 2nd quarter. Dimensional Fund Advisors LP now owns 266,206 shares of the biopharmaceutical company’s stock valued at $64,702,000 after buying an additional 11,027 shares during the period. Amalgamated Bank grew its position in Alnylam Pharmaceuticals by 3.7% during the second quarter. Amalgamated Bank now owns 8,354 shares of the biopharmaceutical company’s stock valued at $2,030,000 after purchasing an additional 301 shares in the last quarter. Summit Trail Advisors LLC bought a new stake in Alnylam Pharmaceuticals in the second quarter worth approximately $226,000. Xponance Inc. grew its position in Alnylam Pharmaceuticals by 7.0% in the second quarter. Xponance Inc. now owns 21,076 shares of the biopharmaceutical company’s stock worth $5,121,000 after acquiring an additional 1,378 shares in the last quarter. Finally, BRITISH COLUMBIA INVESTMENT MANAGEMENT Corp lifted its stake in shares of Alnylam Pharmaceuticals by 61.6% in the second quarter. BRITISH COLUMBIA INVESTMENT MANAGEMENT Corp now owns 24,217 shares of the biopharmaceutical company’s stock worth $5,885,000 after buying an additional 9,234 shares during the last quarter. Hedge funds and other institutional investors own 92.97% of the company’s stock.

Insider Buying and Selling

In related news, CMO Pushkal Garg sold 1,752 shares of the firm’s stock in a transaction that occurred on Thursday, December 12th. The shares were sold at an average price of $251.00, for a total transaction of $439,752.00. Following the sale, the chief marketing officer now owns 15,705 shares in the company, valued at approximately $3,941,955. This trade represents a 10.04 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, EVP Tolga Tanguler sold 1,469 shares of Alnylam Pharmaceuticals stock in a transaction on Tuesday, November 26th. The shares were sold at an average price of $250.98, for a total transaction of $368,689.62. Following the completion of the transaction, the executive vice president now owns 13,191 shares in the company, valued at approximately $3,310,677.18. This trade represents a 10.02 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 10,122 shares of company stock valued at $2,540,455 over the last ninety days. Corporate insiders own 1.50% of the company’s stock.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.